Aluminum is one of the most abundant elements in the environment. Some human exposure is unavoidable -daily intake is largely oral and averages 30-50 mg (1) . Of this, no more than about 7 mg is expected to come from water, based on the maximum reported concentration of aluminum in drinking water (2) and the average consumption of 2 1 water/day. Inhalation exposure is generally negligible, though it can be significant in some occupational settings, as described below. The contrast between widespread occurrence and relatively low intake underscores the importance of speciation in determining the bioavailability of aluminum, as this metal is of limited solubility in its environmentally occurring forms. Despite generally low exposures, the toxicity of aluminum, particularly to the nervous system, is of concern. Much research on aluminum in recent years has focused on its role in the etiology of Alzheimer's disease (AD), but epidemiologic studies attempting to link aluminum with AD in drinking water have been inconclusive and contradictory. This review examines sources of aluminum and the factors determining its absorption, distribution, and elimination in the body, with particular reference to the literature and analytical techniques developed within the last 10 years.
The chemical forms, or species, of aluminum formed in the body have important implications for the balance between the metal's uptake into tissues and its excretion. The study of aluminum speciation has presented a number of major difficulties to researchers. First of all, tracer studies with the aluminum isotope 26Al are very expensive due to the rarity and low activity of the nucleus and also because of the cost of using accelerator mass spectrometry. Second, because of aluminum's ubiquity in the environment, contamination of samples (from dust particles, for example) is difficult to avoid. Finally, aluminum metal, mineral forms, and some salts are very insoluble except at extremes of pH or in the presence of chelating ligands. Aluminum and Alzheimer's Disease There has been considerable interest and controversy concerning the relationship between aluminum in drinking water and AD. A number of studies (3) (4) (5) (6) (7) (8) found correlations between aluminum concentrations in drinking water and the incidence of AD, although the relative risk of AD for those exposed to the highest aluminum concentration, compared to those exposed to the lowest aluminum concentration, was less than 2 in each case. Michel et al. (9) found a relative risk of about 4 for those exposed to the highest aluminum concentration (100 pg/i) compared to the lowest (10 pg/i). Studies failing to find an association were reported by Wood et al. (10) and Wettstein et al. (11) . Although drinking water aluminum constitutes only a small percentage of total daily aluminum intake, Martyn et al. (5) suggested that aluminum in drinking water "is either dissolved or readily brought into solution." The aluminum in drinking water may therefore exist as species that are more readily absorbed than those from other sources of aluminum. However, there are no reports on the oral bioavailability of various aluminum species in water compared to species found in food or other sources. Continuation of the Michel et al. (9) study failed to show an association between drinking water aluminum and cognitive impairment when water pH was not considered. They observed a positive association up to pH 7.3, and a negative association at higher pH (12) , suggesting a pHdependent change in the aluminum species composition in water. In a review of most of the studies of drinking water aluminum and AD, Doll (13) pointed out that low pH was reported in several of the studies showing a positive association between aluminum concentration and AD; one such study was that of Frecker (14) . In contrast, the water had a high pH in one of the studies that failed to show an association (11) .
Odds ratios calculated by Forbes and McAiney (8) , using a logistic regression model for the association between water pH and impaired mental functioning, suggest that medium pH, and to a lesser extent high pH, are protective relative to low pH. However, the authors did not state what variables were being controlled for in the analysis. Forbes et al. (15) and Forbes and McAiney (8) reported results suggesting a protective effect of fluoride on aluminum-associated dementia. This was not substantiated by the results of Jacqmin et al. (12) . A in measurement and extrapolation of data on exposure to aluminum in drinking water. Studies with 26Al to determine the influence of other chemical species and pH of drinking water on oral aluminum bioavailability from food and water might help determine whether enough aluminum is absorbed from water to impact on aluminum body burden. However, such studies will not directly address the role of aluminum in AD. Finally, only a small percentage of total oral daily aluminum intake comes from drinking water.
Specific Sources of Exposure
The aluminum content of foods has been reviewed by Pennington (1/) and Greger (18) . Common food additives containing aluminum are acidic sodium aluminum phosphate, a leavening agent, and basic sodium aluminum phosphate, an emulsifier. Aluminum is also found in food colorings, and anticaking agents may contain aluminosilicates. Processed cheese (a 28-g serving, with 297 pg aluminum/g, has 8 mg) and cornbread (18 mg in a 45-g serving with 400 pig aluminum/g) are major contributors to high aluminum exposures in the American diet. The high aluminum content of these foods is largely due to additives. Another significant dietary source of aluminum is soy-based milk products, which contribute as much as 2.1 mg aluminum/day, based on the typical intake of an infant; this exposure is of particular concern for infants suffering from renal deficiency (18) .
There has been concern in recent years about leaching of aluminum from beverage cans and cookware. Aluminum beverage cans are generally coated with a polymer that prevents leaching. The average concentration of aluminum in cola drinks was found to be only 0.1 pg/g. Aluminum cookware, however, may leach aluminum into highly basic or acidic foods. Tomato sauce cooked in aluminum pans was found to accumulate 3-6 mg aluminum per 100 g serving (18 (17] .
The maximum reported concentration of aluminum in drinking water was 3.5 mg aluminum/1 (2) . Aluminum in U.S. groundwaters ranged from 0.014 to 0.29 mg/l and in untreated surface waters from 0.016 to 1.17 mg/!. Aluminum sulfate is often added as a flocculant to surface waters, resulting in aluminum concentrations in finished drinking water from 0.014 to 2.67 mg/!. Assuming daily consumption of 2 1 of water with an average concentration of 0.1 mg/I, daily intake of aluminum from water would be 0.2 mg (21) .
Aluminum in pharmaceuticals has been reviewed by Yokel (22) . Some over-thecounter pharmaceuticals such as antacids and buffered aspirin contain sufficient aluminum to increase the daily dose significantly. Many (18) .
Dialysis patients can be exposed to large amounts of aluminum via their dialysis fluid. This exposure has been responsible for notable episodes of neurotoxicity (23, 24) . Toxicity associated with dialysis fluid can be largely reduced by removing aluminum from the fluid. Winney et al. (25) found that treatment of dialysate water with reverse osmosis led to decreases in blood aluminum. No new cases of aluminum toxicity occurred in Scotland over 5 subsequent years of follow-up among dialysis patients.
Inhalation exposure of the general population to aluminum in dust is as high as 0.14 mg/day, based on an upper-bound measurement of 5000 ng/m3 [in urban air (2) ] and typical exposure estimates (1 1 air/breath and 20 breaths/min). In contrast, miners, smelters, and other metal workers can be exposed to toxic levels of aluminum through dusts and aerosols. A group of aluminum welders (26) , for example, was exposed to 2.4 mg/m3 of aluminum (8-hr time-weighted average), which results in inhalation of 23 mg over an 8-hr shift.
Miners in northern Ontario between 1944 and 1979 were deliberately exposed via inhalation to aluminum dust as a proprophylactic measure against silicosis (27) . Before each shift, miners were exposed to 20,000 to 34,000 ppm aluminum dust in an enclosed area for 10 Potentiometric data and equilibrium models. Equilibrium models, based on potentiometric data, allow a much more complete (although theoretical) description of species formed in aqueous solutions of aluminum with its ligands, compared to the analytical techniques described in earlier sections. In this technique, formation (or equilibrium) constants are fit to data on change of pH as a function of acid or base added to a solution. These constants can then be used, usually with a computer program, to predict equilibrium concentrations of the postulated species under specified concentrations of aluminum and its ligands, at different pH values. A summary of the predominant aluminum species predicted by each model, in the presence of citrate and range of pH values, is presented in Table 2 .
Berthon and Dayde (43) (42) and in our laboratory (45) through the use of 27A1-NMR. We found further that the trinuclear species indeed appeared at an aluminum:citrate ratio close to 1. We were unable to see this species in solutions where citrate was increased relative to aluminum, however. Furthermore, the equilibrium models described below do not support the existence of this species under high citrate:aluminum ratios such as those found in blood. The published model found to be in best agreement with the experimental data generated in our lab was that of Ohman (44 (58) ; the majority of aluminum absorption, however, is expected to occur in the intestine. In general, the two-step absorption process in the gut is 1) lumen--mucosa and 2) mucosa-+bloodstream.
Aluminum must be in the form of neutral complexes in order to be absorbed by diffusion through the plasma membrane of cells. Ionic aluminum may be absorbed actively by specialized iron-absorption pathways in the gut, as discussed below.
The most important aspect of the gastrointestinal tract with regard to its uptake of aluminum is its change in pH, from 2 to 3 in the stomach to (68) examined absorption of aluminum using a rat everted gut-sac, maintained at pH 7.35-7.42. Absorption was inhibited by dinitrophenol and by the absence of glucose, both of which inhibit cellular respiration, suggesting that aluminum is actively transported out of the intestine. As aluminum behaves similarly to iron in many biological systems (for example, binding to transferrin, discussed below), A13+ may also be taken up via the specialized iron absorption pathways found in the gut. As evidence for this hypothesis, iron deficiency has been found to increase the absorption of aluminum in rats (69) and in renally impaired humans (70 ) . Others, in contrast, found that administering extra iron orally to dialysis patients did not prevent absorption of aluminum from phosphate binders (71) , which would have implied competition between aluminum and iron for absorption. Investigators using an excised gut-section model found that Fe2+ enhanced disappearance of aluminum from the intestinal lumen but did not increase systemic or portal blood aluminum. Fe3+ had no effect on uptake of aluminum from the intestinal lumen (72) .
An iron-binding protein has recently been identified in the duodenal mucosa of rats and humans that may prove to bind to aluminum as well and may thereby account for part of the mechanism of aluminum's uptake at the gut. The protein, named mobilferrin after the Alabama city in which it was discovered, is biochemically and immunologically distinct from both ferritin and transferrin, the two major iron-binding proteins in blood, as assessed by molecular size (56,000 daltons), electrophoretic mobility, and amino acid composition. The dissociation constant for iron from mobilferrin was found to be 8 ance of aluminum from the intestinal lumen. As mentioned above, citrate increased absorption of aluminum as the chloride from the in situ rat gut preparation (60). Froment et al. (75) , in an examination of the mechanism of enhancement of aluminum uptake by citrate, tested the hypothesis that citrate increases the permeability of the tight junctions between intestinal epithelial cells. The investigators excised the duodena of rats, added a solution of ruthenium red, and filled each gut section with either aluminum chloride or aluminum citrate. Examination of the isolated duodenal sections by transmission electron microscopy, in the presence of aluminum citrate, revealed infiltration of ruthenium red through the tight junctions, supporting the hypothesis. In addition, aluminum citrate was found to decrease the transcellular electrical resistance of tight junctions. The investigators did not examine the effect of citrate alone, however.
Schonholtzer et al. (32) Fulton and Jeffery (59) examined the effect of dietary citrate or ascorbate on the absorption of aluminum from drinking water and subsequent tissue concentrations and excretion. They found a dose-dependent increase in aluminum concentration in bone, stomach, intestine, and kidney; liver aluminum was 1.5-fold greater than controls, but there was no dose response, and no aluminum was observed in brain. Ascorbate and citrate increased the concentration of aluminum in tibia, plasma, urine, and feces. Plasma aluminum (about 0.7 jM) was less than 0.5% of total blood bCalculations based on published equilibrium constants. (38, 77) and an 18 kDa component, albindin (38) .
Transferrin, which appears to be the major ligand for aluminum in serum, is a protein of [76] [77] [78] [79] [80] . It is similar in size and amino-acid sequence to albumin, but binds metals (particularly iron) with high specificity at two independent binding sites with similar metal-binding affinities. Binding of a metal ion to transferrin involves deprotonation of three tyrosine (82) , using the MPS-1 system, found that a greater proportion of aluminum was ultrafiltrable in the serum of renally impaired rabbits than in serum from renally competent animals. These results were obtained after incubation of aluminum with rabbit serum in vitro and after an intravenous dose of 100 pmol/kg. These investigators also compared the ultrafiltrability of different aluminum salts in bicarbonate buffer and found that the citrate salt of aluminum remained completely ultrafiltrable up to a total aluminum concentration of 1 mg/ml, while aluminum chloride, nitrate, and lactate salts decreased in ultrafiltrability when total aluminum exceeded 0.01 mg/ml. The concentrations at which aluminum was not totally ultrafiltrable were above the high end of the expected range of serum concentrations. Two of the rabbits in this study died prematurely, possibly (according to the authors) from kidney stones, which could conceivably have consisted of precipitated aluminum.
The similar sizes of transferrin and albumin make it difficult to separate these proteins chromatographically, and failure to add bicarbonate to the elution buffer can decrease or prevent binding of aluminum to transferrin. Many authors have assumed that aluminum binds to both proteins, although evidence discussed below suggests that binding to albumin is insignificant. Martin et al. (83) , based on the weak binding of aluminum to albumin in vitro, the high competition in vivo for albumin binding sites, and the generally low affinity of metal ions for albumin, argued against significant in vivo binding of aluminum to albumin. This would be particularly true under uremic conditions, where potential binding sites on albumin are likely to be occupied by other ligands that accumulate in serum.
Day et al. (30) administered an oral dose of 100 ng 26A1 and about 1 pg 27 (natural aluminum) in sodium citrate solution to a human volunteer. The highest plasma 26Al concentration measured was 0.3 ng/l at 6 hr after ingestion, which suggests that at least 1% of the administered dose (assuming a plasma volume of 3 1) was absorbed (that is, this concentration does not account for aluminum that has already been distributed to tissues or eliminated). The study confirmed, by gel permeation chromatography and anion exchange chromatography at pH 7.4 , that 80% of aluminum in plasma was associated with transferrin, 15% existed as other high molecular weight (>5 kDa) complexes (including albumin), and 5% as low molecular weight species. Ion-exchange chromatography, however, may cause redistribution of ionic aluminum among proteins, so the findings of protein-specific binding are not reliable. Favarato et al. (38) compared the protein binding of aluminum in serum among renally competent workers exposed and unexposed to aluminum and detected a novel protein, dubbed "albindin." This protein picked up more than 40% of serum aluminum after treatment of the serum with desferrioxamine, a powerful chelator of trivalent metallic cations. The amino-acid composition of albindin was distinct from that of transferrin or albumin (38) . The protein-binding profile of aluminum was most complex in the more highly exposed group of workers (classified on the basis of total serum aluminum content). Proteins were identified by polyacrylamide gel electrophoresis (SDS-PAGE), but transferrin and albumin could not be resolved chromatographically (38) . Cochran et al. (39) eluted plasma (which had been spiked with aluminum) from uremic patients on Sephacryl S-300 and assessed the reproducibility of the aluminum/transferrin and aluminum/albumin molar ratios in adjacent elution fractions. They found that the aluminum:
transferrin ratio remained at about 0.12, whereas aluminum/albumin varied from 0.002 to 0.024. These results provided evidence for an association between aluminum and transferrin but not albumin. Transferrin and albumin concentrations were assessed by immunodiffusion, but the methods used were neither described nor referenced. The overall recovery of aluminum was not reported for this experiment, so the significance of the results is uncertain. Dialysis of purified albumin against aluminum solution resulted in the association of 10% of the aluminum with albumin, but when calcium and phosphate were added, no association of aluminum with albumin was detectable. There was no evidence of association of aluminum with either the Sephacryl S-300 or Sephadex G-50 gel used by Cochran et al. (39) .
Role of transferrin. Evidence for transferrin's role as an aluminum carrier is strengthened by a study by Cannata et al. (69) that showed increased aluminum levels in the urine and brain of rats depleted of iron and exposed orally to aluminum). This phenomenon may occur because reduced iron stores lead to increased production of transferrin (84, 85) , a central concept in iron homeostasis. Cannata et al. also found that iron-depleted rat intestinal epithelial cells in vitro contained significantly more aluminum when exposed to transferrin-bound aluminum than did normal cells (69) . Although these results, which show aluminum retention, may reflect aluminum uptake into tissues in general, this evidence is not specifically relevant to the intestine because transferrin is not found in the intestinal lumen.
In vitro analytical chemical methods such as titration have been used to estimate the affinity of aluminum (and other metals) for transferrin and other potential chelators found in serum. Transferrin's affinity for iron is considerably higher than for aluminum [e.g., log Kj = 22.7 and log K2= 22.1 for Fe3+ (83) compared to log K. = 13.72 and log K2 = 12.72 for A13+ (51) .
Because aluminum is present in small amounts in the blood relative to iron concentrations and the capacity of transferrin to bind aluminum (as discussed above), and because iron normally occupies only 30% of available sites on transferrin, aluminum binding to transferrin is not expected to be limited by either the concentration in blood of transferrin (37 PM) (51) or of iron.
Kinetics ofAluminum Uptake by Cells
As in the gastrointestinal tract, aluminum may be taken up into cells by mechanisms similar to those used to take up iron. Foremost among such mechanisms is receptor-mediated uptake of transferrinbound metal, which is saturable. Smallmolecular forms of aluminum may be =_- (86) reported for hepatocytes. Furthermore, aluminum + radiolabeled transferrin (5 pM) was taken up 1.8 times faster than labeled iron-transferrin. Iron uptake reached a plateau by 40 min; aluminum uptake, in contrast, continued to increase after 40 min. In addition, uptake of radiolabeled iron-transferrin was inhibited to a greater extent by addition of unlabeled iron-transferrin than by addition of aluminum-transferrin. The authors postulated a post-uptake feedback mechanism to regulate uptake of iron, which does not appear to have an effect on uptake of aluminum (88 it is thought to undergo a first-pass clearance; that is, much is removed from the bloodstream (91) .
A 41-year-old male volunteer given 26Al intravenously as aluminum citrate excreted all but 10-15% of the aluminum during the first day (31) . However, 7% of the aluminum remained 170 days after the injection, at which time the authors estimated the clearance half-time to be >1 year. Analysis of their results by RSTRIP (92), a program for pharmacokinetic analysis, showed that the terminal elimination half-lives of 26Al that could be estimated in blood and the whole body were about 7 and 300 days, respectively. However, the confidence in this estimate of a 300-day half-life, based on samples collected to only 170 days, is not great. Further analysis of these results suggests that the whole-body aluminum elimination half-life increases with time after exposure. This phenomenon might be explained by the retention of aluminum in a chemical species different from that administered. This species may represent a depot of aluminum that might serve as an aluminum source within the body as it is slowly eliminated from its site of distribution. The whole-body retention of 7% of the administered aluminum 6 months after dosing suggests the prolonged residence of a significant fraction of the administered aluminum. With continued exposure the aluminum depot would be expected to increase. The result would be an increase in aluminum over the human life span, as reported for brain aluminum (93) .
Much of the work conducted thus far on aluminum speciation and distribution has looked at exposures other than ingestion, such as intravenous injection, which can bypass the first-pass effect of the liver. Exposure to dialysis fluid can be considered analogous to intravenous injection because the bloodstream is directly exposed, without being filtered first by the liver.
Implications of speciation for aluminum excretion and aluminum in uremia. The ionic milieu and speciation of aluminum in various body fluids are important to the nature and rate of aluminum elimination by various routes. Aluminum is excreted primarily in the urine, as described above, and to a small degree in the feces (largely as insoluble aluminum phosphate) by way of the portal circulation, liver, and bile. Xu et al. (94) found that biliary excretion accounted for <1% of the aluminum administered as the sulfate to rats, whereas urinary elimination accounted for 9-17%. Greater than 80% of an intravenous dose of Al citrate was eliminated in the urine of a human within 2 weeks, whereas <2% appeared in the feces (31) . The relative contributions of each route of excretion depend in part on such factors as the solubility of aluminum species, presence of complexing ions in serum, renal competence, and aluminum dose. Under normal renal conditions, aluminum should be excreted in urine in the form of small, charged, and thus water-soluble ions or complexes with anions such as citrate and phosphate. Renal. dysfunction could result in the excretion of proteinbound aluminum as well.
Uremic animals and humans seem to be more susceptible to aluminum accumulation and toxicity than renally competent subjects, even in the absence of dialysis. Alfrey et al. (95) found that nondialyzed uremic patients experienced aluminum burdens in liver 6.3 times, spleen 12 times, bone 6.2 times, and brain 1.7 times higher than renally competent patients. Dialyzed uremics and, in particular, dialyzed uremics suffering from encephalopathy, had tissue burdens many times higher than nondialyzed uremics.
Hosokawa and Yoshida (96) performed 5/6 nephrectomy on rats and collected serum 3 months later, without administering additional aluminum above the normal dietary exposure. They found that the average concentration of aluminum in serum was more than 10 times that seen in renally intact rats, and the concentration in kidneys was about 10 times higher. Arieff et al. (97) obtained results similar to Alfrey's human data for concentrations of aluminum in liver of nonuremic dogs and uremic rats but, in contrast, they found that brain aluminum was higher in nondialyzed than dialyzed chronic renal failure patients. No information was given on the aluminum content of the water used in dialysis. It is possible that, if water containing little or no aluminum was used to prepare the dialysis fluid, dialysis could have cleared the blood of small-molecule aluminum, although most aluminum is not in this form. Another explanation could be dietary or therapeutic differences between dialyzed and nondialyzed individuals that would result in the administration or gastrointestinal absorption of different total quantities of aluminum.
There are a number of possible reasons for the observation that uremia leads to an increased body burden of aluminum. The simplest explanation is that, in having lower excretory capacity, uremics might simply not be able to rid themselves of aluminum efficiently, allowing it more time to be distributed to peripheral tissues. Yokel and McNamara (82) found that the systemic clearance was significantly lower in renally impaired animals than renally intact (39 compared to 53 ml/kg-hr), whereas Meirav et al. (29) 
systemic clearance of aluminum in a renally impaired rat to that in two normal rats and found that the renal clearance was similar. Ittel et al. (98) found that urinary excretion of aluminum was greater in uremic than in control rats, but ascribed their results to greater absorption of aluminum rather than greater clearance. A mechanism postulated for an increase in absorption was secondary hyperparathyroidism. The aluminum toxicity experienced by uremics may also be iatrogenic, through exposure to aluminum in dialysis fluid. This possibility has already been addressed in the clinical setting: dialysis fluid is now made from low-aluminum water, and patients appear to suffer less aluminum toxicity as a result (1) .
An alternative explanation for Ittel's observation of increased excretion of aluminum in uremia is that the free, or ultrafiltrable, fraction is increased relative to the protein-bound fraction. One study found that a greater percentage of the aluminum added to serum from renally impaired rabbits was free than in serum from normal rabbits (82 (79) reported that the serum transferrin concentration in dialysis patients is about 30 pM.
Given that serum aluminum concentrations are higher than normal in these patients, this reduction in aluminum-binding capacity may have implications for aluminum speciation.
As uremics also experience higher aluminum tissue burden and toxicity (95) , it may be that this fraction is more available to tissues than the protein-bound fraction, although tissue burden may reflect selective retention rather than increased bioavailability. Another (101) . Transferrin is believed to play a role in the development of myelinated cells. In the presence of other, smaller complexes, however, aluminum could cross the blood-brain barrier. A case study was reported of several renal dialysis patients suffering from bone aluminum toxicity who were treated with desferrioxamine, an iron-chelating drug that also efficiently chelates aluminum. The subjects experienced neurological symptoms resembling dialysis dementia; several of them died. The investigators conjectured that the resulting desferrioxamine-aluminum complex, which is much smaller and more soluble than aluminum-protein complexes, had distributed into the brain (102). Yokel et al. (103) supported this hypothesis in a rat study using microdialysis probes to monitor aluminum-desferrioxamine distribution into various tissues, including the brain. Allen and Yokel (104 ) used in vivo microdialysis to compare the permeabilities of aluminum and gallium through the blood-brain barrier with a view to using gallium as a model for aluminum. They found aluminum and gallium permeation to be dissimilar. Gallium, although attractive because it possesses usable radioisotopes, therefore does not seem an appropriate model for aluminum penetration into the brain. Specifically, these investigators found that aluminum permeates the brain primarily at the cerebral capillaries, whereas gallium permeates equally at the cerebral capillaries and at the choroid plexuses. The permeation of aluminum was nonsaturable, suggesting a nonspecific process such as diffusion or pinocytosis of smallmolecule aluminum rather than binding of aluminum-transferrin to cell-surface receptors. The permeation of aluminum into the brain could, however, be a combination of specific and nonspecific processes and still appear nonsaturable overall, so there still may be a role for transferrin.
Farrar et al. (105) used HPLC and gel electrophoresis to study the binding of radioactive gallium (which they presumed to be analogous to aluminum) to transferrin. Binding was lower in people with either AD or Down's syndrome than in normal subjects. The authors postulate that reduced binding of gallium, and presumably aluminum, to transferrin could lead to increased uptake of the metal across the blood-brain barrier as a neutral citrate complex. As discussed above, aluminum appears to be taken up in a nonsaturable fashion (i.e., nonspecifically), at least at the cerebral capillaries (104).
Roskams and Connor (100) examined the binding of aluminum-transferrin and iron-transferrin to homogenized rat brain and found evidence of a receptor that binds both. Dissociation constants (Kd) were 5.7 nM for iron-transferrin and 13.1 nM for aluminum-transferrin. The affinity of this receptor for aluminum-transferrin, although lower than that for iron-transferrin, is still higher than the affinity of receptors in other cells (such as hepatocytes and lymphocytes) for iron-transferrin. Unfortunately, homogenized rat brain is probably not a good model for the blood-brain barrier. These authors suggested that aluminum's toxicity in the brain might involve, at least in part, disruption of normal iron homeostasis and iron-dependent cellular processes. Fleming and Joshi (106) found that aluminum can interfere with the rate of binding of iron to ferritin, an iron-storage protein, in support of Roskams and Connor's suggestion (100).
Summary and Conclusions
A small fraction (0.1-1%) of aluminum appears to be absorbed gastrointestinally from the diet, possibly by iron-absorption pathways. Upon -~~ilitg species postulated is AI(OH)3' (aq), whose existence has not been established and which, in any case, appears, based on modeling data, not to constitute a large fraction of soluble aluminum species in serum.
The charged, soluble aluminum species are unavailable for diffusion into tissues, but are presumably readily excretable. Receptors for transferrin, on the other hand, exist in many cells, including at the blood-brain barrier, and provide a means for uptake of transferrin-bound aluminum into tissues. Radionuclides of aluminum are expensive, making tracer studies difficult; atomic absorption spectroscopy is the usual means of quantitating aluminum in biological samples. Radioactive gallium has been used as a model for aluminum uptake, but its behavior does not appear to be strictly comparable. Uptake of aluminum into brain and bone lead to toxicity. Aluminum toxicity is of particular concern to individuals with kidney impairment, in whom aluminum concentrations are higher.
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